|
Affiliation |
Faculty of Medicine School of Medicine Department of Clinical Neuroscience, Neurosurgery |
|
Title |
Assistant Professor |
|
External Link |
|
|
Related SDGs |
|
SAITO Kiyotaka
|
|
|
Degree 【 display / non-display 】
-
Doctor of Philosophy ( 2019.3 University of Miyazaki )
-
学士（医学） ( 2007.3 宮崎大学 )
Papers 【 display / non-display 】
-
Cerebral radiation necrosis successfully treated with high-dose bevacizumab Reviewed
Kugimiya K., Tsubouchi H., Saito K., Kadota Y., Azuma M., Sakai K., Oda Y., Sumiyoshi M., Yanagi S., Miyazaki T.
Respiratory Medicine Case Reports 58 102282 2025.1
Language：English Publishing type：Research paper (scientific journal) Publisher：Respiratory Medicine Case Reports
Cerebral radiation necrosis (CRN) is a late complication that can occur after the treatment of a brain tumor with focal radiation therapy, particularly stereotactic radiosurgery (SRS). Since an excessive production of vascular endothelial growth factor (VEGF) from necrotic lesions is a possible etiology of radiation necrosis, the anti-VEGF antibody bevacizumab has been reported as an effective treatment option. We report a case of a 71-year-old Japanese male with CRN following SRS, successfully treated with bevacizumab. He had presented with aphasia and right lower-limb muscle weakness 6 years after a left upper lobectomy for lung adenocarcinoma. Head magnetic resonance imaging (MRI) showed a metastatic brain tumor in the left temporal lobe. A craniotomy and pre- and post-operative SRS treatments were performed to relieve his neurological symptoms. Although initial symptom improvement was observed, the patient developed lower-limb muscle weakness and aphasia symptoms 7 months after the last SRS treatment.<sup>11</sup>C-methionine positron emission tomography (PET) and<sup>18</sup>F-fluorodeoxyglucose PET scans showed no abnormal uptake, leading to a diagnosis of CRN. The patient was treated with bevacizumab 15 mg/kg every 3 weeks for six cycles. The bevacizumab treatment resulted in an improvement of neurological symptoms and lesions showing gadolinium-enhancing effects and high-signal areas on T2-weighted fluid attenuated inversion recovery on MRI. The improvement was maintained 44 months after the completion of the last bevacizumab treatment. Although no definitive number of cycles and dosage of bevacizumab for CRN have been established, this case suggests that administering six cycles of bevacizumab may prevent long-term recurrence of CRN.
-
Saito K., Yokogami K., Maekawa K., Sato Y., Yamashita S., Matsumoto F., Mizuguchi A., Takeshima H.
Human Cell 34 ( 2 ) 644 - 653 2021.3
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Human Cell
TP53 mutations are important molecular markers in diffuse astrocytic tumors and medulloblastomas. We examined the efficacy of a pre-screening method for high-resolution melting (HRM) analysis of TP53 mutation before direct sequencing using samples from patients with diffuse glioma. Surgical samples from 64 diffuse gliomas were classified based on the 2016 World Health Organization (WHO) histopathological grading system and the cIMPACT-NOW (consortium to inform molecular and practical approaches to CNS tumor taxonomy-not official WHO) update. TP53 mutations from exon 5 to exon 8 were assessed by direct sequencing. The results of HRM and p53 immunohistochemistry (IHC) analysis were compared by recording the sensitivity, specificity, and false negative and false positive rates. Direct sequencing detected TP53 mutations in 18 of 64 samples (28.1%): diffuse astrocytoma, IDH-mutant (n = 3); diffuse astrocytoma, IDH-wild type (n = 1); anaplastic astrocytoma, IDH-mutant (n = 3); anaplastic astrocytoma, IDH-wild type (n = 4); and glioblastoma, IDH-wild type (n = 7). A total of 22 mutations was detected in the 18 samples; 4 samples exhibited duplicate missense mutations. Sensitivity and specificity were 0.96 and 0.96, respectively, for HRM analysis; they were 0.89 and 0.52, respectively, for p53 IHC. Overall accuracy was 0.98 for HRM and 0.63 for IHC. HRM analysis is a good pre-screening method for the detection of TP53 mutation before direct sequencing.
-
Urata S., Yoshikawa N., Saito K., Tazaki T., Ohno R., Takeshima H., Ikeda R.
Journal of Clinical Pharmacy and Therapeutics 2021
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Journal of Clinical Pharmacy and Therapeutics
What is known and objective: Methotrexate (MTX) is an important agent for the treatment of primary central nervous system lymphomas (PCNSL) but needs to be given in big doses by intravenous infusions to achieve therapeutic concentrations in the cerebrospinal fluid. However, co-administration with many drugs may delay the excretion of MTX which may cause serious adverse effects if the serum concentration exceeds 0.1 µmol/L 72 h after an intravenous infusion. Case summary: A 67-year-old Japanese female with PCNSL was treated with high-dose MTX-based chemotherapy. The serum MTX concentration 72 h post-infusion was 0.153 µmol/L when she was taking levofloxacin (LVFX) but <0.1 µmol/L 72 h after 4 subsequent infusions when she was not taking LVFX. She was given many other drugs but the timing of the short course of LVFX and the fact that ciprofloxacin also delays MTX excretion suggests that LVFX was the cause. What is new and conclusion: Co-administration of LVFX may delay the excretion of MTX. Therefore, serum concentrations of MTX should be monitored to help prevent and improve the management of potentially serious MTX drug-drug interaction.
DOI： 10.1111/jcpt.13425
-
Selection of surgical approach for cerebellar hemangioblastomas based on venous drainage patterns
Watanabe T., Suematsu Y., Saito K., Takeishi G., Yamashita S., Ohta H., Yokogami K., Takeshima H.
Neurosurgical Review 2021
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Neurosurgical Review
Cerebellar hemangioblastomas remain surgically challenging because of the narrow, deep surgical corridors and tumor hypervascularity. Various surgical approaches are used according to the location, but optimal approaches have not been established. We propose a system of surgical approaches based on the venous drainage systems to facilitate surgical planning and achieve acceptable neurological outcomes. Cerebellar hemangioblastomas were divided into five types based on the main drainage systems: suboccipital hemangioblastomas draining to the transverse sinus (TS) or torcula, tentorial hemangioblastomas draining to the tentorial sinus or straight sinus, petrosal hemangioblastomas draining to the superior petrosal sinus (SPS), quadrigeminal hemangioblastomas draining to the galenic system, and tonsillar hemangioblastomas draining to the TS or torcula in conjunction with jugular bulb or SPS. Microsurgical approaches and patient outcome were retrospectively reviewed according to this classification. This study included 17 patients who underwent 21 operations for resection of 19 cerebellar hemangioblastomas, classified into 9 suboccipital, 4 tentorial, 2 petrosal, 2 quadrigeminal, and 2 tonsillar. Standard suboccipital craniotomies were utilized for suboccipital hemangioblastomas, the occipital transtentorial approach (OTA), and supracerebellar infratentorial approach for tentorial hemangioblastomas, the retrosigmoid approach for petrosal hemangioblastomas, OTA for quadrigeminal hemangioblastomas, and midline suboccipital approach for tonsillar hemangioblastomas. Gross total resection was achieved in all patients except one. Two patients with large hemangioblastomas (tonsillar and quadrigeminal) required second-stage operation which finally achieved gross total removal. No single approach had a significantly higher incidence of postoperative neurological deficits. Selection of the optimum surgical approach for cerebellar hemangioblastomas was successful based on the main drainage systems. Understanding of tumor growth and extension with respect to the venous drainage system is critical to select the appropriate surgical approach.
-
Tamura M., Saito K., Irisa G., Ohta H., Yokogami K., Sakai K., Takeshima H.
No shinkei geka. Neurological surgery 48 ( 6 ) 547 - 552 2020.6
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：No shinkei geka. Neurological surgery
We report a case of anterior cranial fossa dural arteriovenous fistula(ACF-DAVF)in a patient whose diagnosis was made according to characteristic findings on arterial spin labeling(ASL)MRI. CASE:A 68-year-old man was admitted to our hospital because of intractable epilepsy. Based on the initial MRI findings, an initial diagnosis of limbic encephalitis was made. Steroids and anticonvulsant drugs were administered;however, the seizures could not be controlled. A second MRI with ASL revealed abnormal vessel signals in the base segments of the left frontal and temporal lobes toward the basal vein of Rosenthal. Digital subtraction angiography(DSA)revealed an arteriovenous shunt in the left anterior cranial fossa, which drained toward the medial side of the left temporal lobe. A diagnosis of ACF-DAVF with status epilepticus was made, and the main drainer was cauterized. After the surgical procedure, the epilepsy was controlled with antiepileptic drugs, and postoperative MRI revealed obliteration of ACF-DAVF, disappearance of the high-intensity area on FLAIR sequences, and disappearance of the high-intensity signal area on ASL.
Presentations 【 display / non-display 】
-
診断に苦慮したけいれん発作型前頭蓋基底部硬膜動静脈瘻の1例．
齋藤清貴
第44回日本脳卒中学会学術集会
Event date： 2019.3.21 - 2019.3.23
Language：Japanese Presentation type：Oral presentation (general)
-
Efficacy of ICE plus Bevacizumab Therapy for Temozolomide-Resistant Anaplastic Astroblastoma: Case Report.
齋藤清貴
第36回日本脳腫瘍病理学会
Event date： 2018.9.25 - 2018.9.27
Language：Japanese Presentation type：Oral presentation (general)
-
Diffuse gliomaにおける術中5‐ALA 蛍光性とMRI画像所見の関連性． International conference
齋藤清貴
第41回日本脳神経CI学会総会
Event date： 2018.3.2 - 2018.3.3
Language：Japanese Presentation type：Oral presentation (general)
-
HRM法を用いた神経膠腫のTP53変異解析．
齋藤清貴，横上聖貴，山下真治，水口麻子，松元文孝，竹島秀雄
第18回日本分子脳神経外科学会
Event date： 2017.8.25 - 2017.8.26
Language：Japanese Presentation type：Oral presentation (general)
-
Anaplastic astroblastomaの1例．
齋藤清貴
第35回日本脳腫瘍病理学会
Event date： 2017.5.19 - 2017.5.20
Language：Japanese Presentation type：Oral presentation (general)
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
グリオブラストーマにおけるRTN4RのlncRNA機能とPMT抑制機構の解明
Grant number：25K23879 2025.04 - 2027.03
独立行政法人日本学術振興会 科学研究費基金 研究活動スタート支援
Authorship：Principal investigator
-
IDH1変異グリオーマにおけるポルフィリン代謝調節機構の解明
Grant number： 18K16564 2018 - 2021.03
独立行政法人日本学術振興会 科学研究費基金 若手研究(B)
Authorship：Principal investigator